CN115003668A - Macrocyclic compounds as KRAS inhibitors - Google Patents
Macrocyclic compounds as KRAS inhibitorsDownload PDFInfo
- Publication number
- CN115003668A CN115003668ACN202180010403.2ACN202180010403ACN115003668ACN 115003668 ACN115003668 ACN 115003668ACN 202180010403 ACN202180010403 ACN 202180010403ACN 115003668 ACN115003668 ACN 115003668A
- Authority
- CN
- China
- Prior art keywords
- macrocyclic compounds
- kras inhibitors
- macrocyclic compound
- kras
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Translated fromChinesePCT国内申请，说明书已公开。PCT domestic application, the description has been published.
Claims (17)
Translated fromChineseApplications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020100715283 | 2020-01-21 | ||
| CN202010071528 | 2020-01-21 | ||
| CN202010514548 | 2020-06-08 | ||
| CN2020105145483 | 2020-06-08 | ||
| CN202010986192 | 2020-09-18 | ||
| CN2020109861923 | 2020-09-18 | ||
| PCT/CN2021/073151WO2021147967A1 (en) | 2020-01-21 | 2021-01-21 | Macrocyclic compound serving as kras inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115003668Atrue CN115003668A (en) | 2022-09-02 |
Family
ID=76993171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180010403.2APendingCN115003668A (en) | 2020-01-21 | 2021-01-21 | Macrocyclic compounds as KRAS inhibitors |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115003668A (en) |
| WO (2) | WO2021147967A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113248521A (en)* | 2020-02-11 | 2021-08-13 | 上海和誉生物医药科技有限公司 | K-RAS G12C inhibitor and preparation method and application thereof |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP3849538A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3849536A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| JP7451419B2 (en) | 2018-10-26 | 2024-03-18 | 大鵬薬品工業株式会社 | Novel indazole compound or salt thereof |
| EA202190630A1 (en) | 2018-12-05 | 2021-10-11 | Мирати Терапьютикс, Инк. | COMBINED THERAPY METHODS |
| JP7592601B2 (en) | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | KRAS G12C inhibitors |
| PH12022550469A1 (en) | 2019-08-29 | 2023-02-27 | Array Biopharma Inc | Kras g12d inhibitors |
| CN114761012B (en) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | Combination therapy |
| GEP20247710B (en) | 2019-10-28 | 2024-12-25 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12c mutant |
| CN119462626A (en) | 2019-12-20 | 2025-02-18 | 米拉蒂治疗股份有限公司 | SOS1 inhibitors |
| CN116209438A (en) | 2020-09-03 | 2023-06-02 | 锐新医药公司 | Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors |
| CA3190944A1 (en) | 2020-09-11 | 2022-03-17 | Mirati Therapeutics, Inc. | Crystalline forms of a kras g12c inhibitor |
| CN116457358A (en) | 2020-09-15 | 2023-07-18 | 锐新医药公司 | Indole derivatives as RAS inhibitors for the treatment of cancer |
| US12162893B2 (en) | 2020-09-23 | 2024-12-10 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CA3198885A1 (en) | 2020-12-15 | 2022-06-23 | Xiaolun Wang | Azaquinazoline pan-kras inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN116249703A (en)* | 2020-12-21 | 2023-06-09 | 上海和誉生物医药科技有限公司 | Macrocyclic K-RAS G12C inhibitor, preparation method and application thereof |
| AR125782A1 (en) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | RAS INHIBITORS |
| WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| WO2022233316A1 (en)* | 2021-05-06 | 2022-11-10 | 南京明德新药研发有限公司 | Twelve-membered macrocyclic compound |
| CN115894520A (en)* | 2021-09-23 | 2023-04-04 | 上海和誉生物医药科技有限公司 | A macrocyclic K-RAS G12C inhibitor, its preparation method and pharmaceutical application |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| JP2025500878A (en) | 2021-12-17 | 2025-01-15 | ジェンザイム・コーポレーション | PYRAZOLO-PYRAZINE COMPOUNDS AS SHP2 INHIBITORS |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN119136806A (en) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | Methods for treating immune-refractory lung cancer |
| KR20250022133A (en) | 2022-06-10 | 2025-02-14 | 레볼루션 메디슨즈, 인크. | macrocyclic RAS inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| WO2024102421A2 (en) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| CN120500482A (en)* | 2022-11-14 | 2025-08-15 | 美国安进公司 | Macrocyclic KRAS inhibitors and methods of use |
| TW202504611A (en) | 2023-03-30 | 2025-02-01 | 美商銳新醫藥公司 | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024216048A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024216016A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| TW202508595A (en) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025067459A2 (en) | 2023-09-29 | 2025-04-03 | D3 Bio (Wuxi) Co., Ltd. | Therapies for the treatment of cancer |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025194057A1 (en)* | 2024-03-14 | 2025-09-18 | Amgen Inc. | Macrocyclic compounds as modulators of kras and uses thereof |
| WO2025194054A1 (en)* | 2024-03-14 | 2025-09-18 | Amgen Inc. | Spirocyclic compounds as modulators of kras and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190374542A1 (en)* | 2018-06-12 | 2019-12-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| CN113248521A (en)* | 2020-02-11 | 2021-08-13 | 上海和誉生物医药科技有限公司 | K-RAS G12C inhibitor and preparation method and application thereof |
| CN114008037A (en)* | 2019-06-24 | 2022-02-01 | 广东新契生物医药科技有限公司 | Heterocyclic compounds as KRAS G12C inhibitors |
| CN114867726A (en)* | 2019-10-28 | 2022-08-05 | 默沙东公司 | Small molecule inhibitors of KRAS G12C mutant |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190272A1 (en)* | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| CA3075046A1 (en)* | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| MX2020010836A (en)* | 2018-05-04 | 2021-01-08 | Amgen Inc | Kras g12c inhibitors and methods of using the same. |
| WO2019241157A1 (en)* | 2018-06-11 | 2019-12-19 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
- 2021
- 2021-01-21CNCN202180010403.2Apatent/CN115003668A/enactivePending
- 2021-01-21WOPCT/CN2021/073151patent/WO2021147967A1/ennot_activeCeased
- 2021-01-21WOPCT/CN2021/073149patent/WO2021147965A1/ennot_activeCeased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190374542A1 (en)* | 2018-06-12 | 2019-12-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| CN114008037A (en)* | 2019-06-24 | 2022-02-01 | 广东新契生物医药科技有限公司 | Heterocyclic compounds as KRAS G12C inhibitors |
| CN114867726A (en)* | 2019-10-28 | 2022-08-05 | 默沙东公司 | Small molecule inhibitors of KRAS G12C mutant |
| CN113248521A (en)* | 2020-02-11 | 2021-08-13 | 上海和誉生物医药科技有限公司 | K-RAS G12C inhibitor and preparation method and application thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113248521A (en)* | 2020-02-11 | 2021-08-13 | 上海和誉生物医药科技有限公司 | K-RAS G12C inhibitor and preparation method and application thereof |
| CN113248521B (en)* | 2020-02-11 | 2023-07-18 | 上海和誉生物医药科技有限公司 | K-RAS G12C inhibitor and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021147965A1 (en) | 2021-07-29 |
| WO2021147967A1 (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115003668A (en) | Macrocyclic compounds as KRAS inhibitors | |
| CN115698022A (en) | Five-membered heteroaryl imidazole compounds and their applications | |
| CN115667238A (en) | A five-membered ring derivative and its application in medicine | |
| CN115335372A (en) | Octahydropyrazinodiazinidinediones | |
| CN115335379A (en) | Spiro-containing quinazoline compounds | |
| CN114616232A (en) | Azepadinopyrimidine derivatives and medical application thereof | |
| CN116113632A (en) | Heterocyclic derivatives, their preparation methods and their medicinal uses | |
| CN115298174A (en) | Pyrimido-heterocyclic compounds and application thereof | |
| CN114174282A (en) | Pyridazinone derivatives as thyroxine receptor-beta agonists and uses thereof | |
| CN113853373A (en) | Substituted heterocyclic and cyclic compounds, their preparation and medical use | |
| CN115315423A (en) | Substituted aryl compounds | |
| CN115551867A (en) | Fused tricyclic compound, its pharmaceutical composition and use | |
| CN114728974A (en) | Pyrrolopyrimidine compounds as BTK inhibitors and application thereof | |
| CN115916765A (en) | Pyridine or pyrimidine derivatives, preparation method and use thereof | |
| CN112689627A (en) | Tricyclic substituted piperidinediones | |
| CN115279760A (en) | Novel HPK1 inhibitor and preparation method and application thereof | |
| CN114829365A (en) | Thiazololactam compounds as ERK inhibitors and application thereof | |
| CN114761411A (en) | Spiro compound serving as ERK inhibitor and application thereof | |
| CN115697994A (en) | Fused quinazoline derivative, preparation method and medical application thereof | |
| CN116134028A (en) | Compound capable of degrading BTK kinase, preparation method and pharmaceutical application thereof | |
| CN115397822A (en) | CBP/EP300 inhibitors and uses thereof | |
| CN113474345A (en) | Nitrogen-containing spiro derivatives as RET inhibitors | |
| CN114728967A (en) | Tri-heterocyclic compounds as JAK inhibitors and application thereof | |
| CN111788205A (en) | Pyrazolopyrimidine derivatives and uses thereof | |
| CN113825755A (en) | Imidazopyridines as IRAK4 Inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | Application publication date:20220902 |